Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
BACKGROUND
We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.


METHODS
Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.


RESULTS
The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.


CONCLUSIONS
Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.
Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland. Electronic address: aurelius.omlin@kssg.ch.
Aurelius
A
Omlin
Tulane University, Department of Medicine and Urology, New Orleans, LA.
Oliver
O
Sartor
Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland.
Christian
C
Rothermundt
Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland.
Richard
R
Cathomas
Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, ICR, Sutton, UK.
Johann S
JS
De Bono
Sanofi-Aventis, Bridgewater, NJ.
Liji
L
Shen
Sanofi-Aventis, Bridgewater, NJ.
Zhen
Z
Su
Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland.
Silke
S
Gillessen
D000505:Alopecia / Q000453:epidemiology / Q000209:etiology; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D004408:Dysgeusia / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D008297:Male; D009260:Nail Diseases / Q000453:epidemiology / Q000209:etiology; D010523:Peripheral Nervous System Diseases / Q000453:epidemiology / Q000209:etiology; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects*
D043823:Taxoids; D000077143:Docetaxel; C552428:cabazitaxel
Adverse event; Cabazitaxel; Castration-resistant prostate cancer; Clinical trial; Docetaxel